Investor News

Launch of Evinco Therapeutics: A pioneering biotech company advancing immune therapies for Alzheimer’s disease

Launch of Evinco Therapeutics: A pioneering biotech company advancing immune therapies for Alzheimer’s disease

Evinco Therapeutics is an Australian start-up on a mission to transform the treatment of Alzheimer’s disease and other neuroinflammatory conditions

Melbourne, Australia, 4 December 2025 – An exciting chapter in medical innovation begins today with the official launch of Evinco Therapeutics Pty Ltd (“Evinco” or “Company”), a Melbourne-based biotechnology company developing advanced immune-based therapies for […]

Christine Filippis2025-12-04T15:17:50+11:00December 4th, 2025|

Cartherics appoints Dr Ian Nisbet as Chief Executive Officer

Cartherics appoints Dr Ian Nisbet as Chief Executive Officer

Dr Ian Nisbet appointed as Chief Executive Officer
Prof Alan Trounson AO will move into the role of Deputy Chair of the Board

Melbourne, Australia, 28 November 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian […]

Christine Filippis2025-11-28T10:15:10+11:00November 28th, 2025|

Cartherics Unveils State-Of-The-Art Cleanroom Facility for Cell Therapy Manufacturing

Cartherics Unveils State-Of-The-Art Cleanroom Facility for Cell Therapy Manufacturing

Melbourne, Australia, 6 August 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune stem cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.

The facility was officially opened by the […]

Christine Filippis2025-08-06T16:32:36+10:00August 6th, 2025|

Cartherics to present at the 2025 BIO International Convention

Cartherics to present at the 2025 BIO International Convention

Cartherics’ Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16^th June, 2025 at 1.30pm (US EDT).

Melbourne, Australia, 28 May 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]

Christine Filippis2025-05-28T12:11:40+10:00May 28th, 2025|

Cartherics appoints new Board Chair and Non-Executive Director

Cartherics appoints new Board Chair and Non-Executive Director

Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director

Melbourne, Australia, 16 April 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce the appointment of Prof. Bryan R.G. Williams […]

Christine Filippis2025-05-08T09:47:26+10:00April 16th, 2025|

Cartherics awarded US$300K G-Rex grant to accelerate clinical manufacturing of CAR-NK cell therapy

Cartherics awarded US$300K G-Rex grant to accelerate clinical manufacturing of CAR-NK cell therapy

Cartherics has received a US$300K G-Rex grant to support its ‘in house’ manufacturing program

Funding will enable Cartherics to generate crucial data required for its IND submission to the FDA for CTH-401, paving the way for clinical trials in ovarian cancer.

Melbourne, Australia, 18 December 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), […]

Christine Filippis2024-12-18T12:01:31+11:00December 18th, 2024|

Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs

Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs

Financing round was significantly oversubscribed by existing investors and new private investors.

Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.

Melbourne, Australia, 1 October 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a […]

Christine Filippis2024-10-01T09:27:29+10:00October 1st, 2024|

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

Innovative Cancer Solutions: Cartherics’ Patented Immunotherapy Approach

In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work in developing cell therapy treatments for cancer. He discusses Cartherics’ expanding intellectual property portfolio, the impact of targeting TAG-72 on treating ovarian and gastric cancers as well as recent collaborations and the growing market for […]

Christine Filippis2024-06-14T16:20:03+10:00June 14th, 2024|

Cartherics secures Australian patent for innovative cancer cell therapy

Cartherics secures Australian patent for innovative cancer cell therapy

Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically modified cells and uses thereof”, providing patent support for multiple development candidates in the […]

Christine Filippis2024-06-12T13:49:21+10:00June 12th, 2024|

Cartherics granted European patent for multiple development candidates

Cartherics granted European patent for multiple development candidates

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.

The European Patent No. 3708587 B1, titled ‘Genetically […]

Christine Filippis2024-05-23T15:21:41+10:00May 23rd, 2024|

About us

Sign up to our newsletter